Symbols / BTAI
BTAI Chart
About
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 35.87M |
| Enterprise Value | 108.98M | Income | -68.21M | Sales | 752.00K |
| Book/sh | -4.45 | Cash/sh | 1.65 | Dividend Yield | — |
| Payout | 0.00% | Employees | 37 | IPO | — |
| P/E | — | Forward P/E | -0.59 | PEG | — |
| P/S | 47.69 | P/B | -0.37 | P/C | — |
| EV/EBITDA | -2.17 | EV/Sales | 144.91 | Quick Ratio | 0.96 |
| Current Ratio | 1.18 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -9.29 | EPS next Y | -2.78 | EPS Growth | — |
| Revenue Growth | -54.20% | Earnings | 2026-03-26 | ROA | -67.31% |
| ROE | — | ROIC | — | Gross Margin | -28.19% |
| Oper. Margin | -143.20% | Profit Margin | 0.00% | Shs Outstand | 21.87M |
| Shs Float | 19.47M | Short Float | 7.17% | Short Ratio | 2.40 |
| Short Interest | — | 52W High | 8.08 | 52W Low | 1.17 |
| Beta | 0.20 | Avg Volume | 515.60K | Volume | 328.75K |
| Target Price | $15.25 | Recom | Buy | Prev Close | $1.63 |
| Price | $1.64 | Change | 0.61% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.25
Mean price target
2. Current target
$1.64
Latest analyst target
3. DCF / Fair value
$-35.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.64
Low
$1.00
High
$38.00
Mean
$15.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-09-12 | main | Mizuho | Neutral → Neutral | $4 |
| 2025-08-28 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-08-15 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-07-15 | reit | LUCID CAPITAL MARKETS | Buy → Buy | $66 |
| 2025-06-23 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-19 | init | Rodman & Renshaw | — → Buy | $65 |
| 2025-01-30 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-01-07 | down | B of A Securities | Buy → Underperform | $0 |
| 2025-01-06 | main | Canaccord Genuity | Buy → Buy | $5 |
| 2024-10-21 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-09-06 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-30 | main | Canaccord Genuity | Buy → Buy | $7 |
| 2024-08-09 | main | UBS | Neutral → Neutral | $1 |
| 2024-08-08 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-06-27 | main | Canaccord Genuity | Buy → Buy | $7 |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-23 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
- Doctors tackle 100M Alzheimer’s agitation episodes in new BioXcel webcast - Stock Titan hu, 19 Feb 2026 12
- Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire hu, 15 Jan 2026 08
- BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance Wed, 12 Nov 2025 08
- New Analyst Forecast: $BTAI Given $66.0 Price Target - Nasdaq ue, 15 Jul 2025 07
- BioXcel Therapeutics Stock (BTAI) Opinions on Phase 3 SERENITY Trial Completion | BTAI Stock News - Quiver Quantitative Wed, 06 Aug 2025 07
- BioXcel stock down despite late-stage trial win (BTAI:NASDAQ) - Seeking Alpha Wed, 27 Aug 2025 07
- BTAI - Bioxcel Therapeutics Inc Latest Stock News & Market Updates - Stock Titan ue, 20 Jan 2026 08
- BIOXCEL THERAPEUTICS Earnings Results: $BTAI Reports Quarterly Earnings - Quiver Quantitative Wed, 12 Nov 2025 08
- BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance ue, 12 Aug 2025 07
- At-home relief for agitation: FDA review sought for IGALMI film - Stock Titan ue, 20 Jan 2026 08
- 1 Top Penny Stock to Watch Now - Yahoo Finance Sat, 17 Jan 2026 08
- BioXcel (NASDAQ: BTAI) plans Q1 2026 sNDA for IGALMI at‑home use after Phase 3 data - Stock Titan Wed, 12 Nov 2025 08
- BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress - Yahoo Finance Fri, 11 Jul 2025 07
- SERENITY At-Home pivotal trial completed: BioXcel to ring Nasdaq closing bell Oct 14, 2025 - Stock Titan Mon, 13 Oct 2025 07
- Drugmaker moves to bring at-home relief for bipolar agitation - Stock Titan Wed, 07 Jan 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 68 | — | — | STEINHART RICHARD I | Chief Financial Officer | — | 2025-12-15 00:00:00 | D | nan |
| 1 | 383 | — | — | MEHTA VIMAL | Chief Executive Officer | — | 2025-12-15 00:00:00 | D | nan |
| 2 | 68 | — | — | YOCCA FRANK D. PH.D. | Officer | — | 2025-12-15 00:00:00 | D | nan |
| 3 | 68 | — | — | RODRIGUEZ JAVIER | Officer | — | 2025-12-15 00:00:00 | D | nan |
| 4 | 1694 | — | — | MACK DAVID J | Director | — | 2025-10-31 00:00:00 | D | nan |
| 5 | 1694 | — | — | MACK DAVID J | Director | — | 2025-09-30 00:00:00 | D | nan |
| 6 | 68 | — | — | STEINHART RICHARD I | Chief Financial Officer | — | 2025-09-15 00:00:00 | D | nan |
| 7 | 382 | — | — | MEHTA VIMAL | Chief Executive Officer | — | 2025-09-15 00:00:00 | D | nan |
| 8 | 68 | — | — | YOCCA FRANK D. PH.D. | Officer | — | 2025-09-15 00:00:00 | D | nan |
| 9 | 68 | — | — | RODRIGUEZ JAVIER | Officer | — | 2025-09-15 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -41.72M | -161.26M | -157.22M | -106.59M |
| TotalUnusualItems | -2.44M | -4.16M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -2.44M | -4.16M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -59.60M | -179.05M | -165.76M | -106.93M |
| ReconciledDepreciation | 309.00K | 318.00K | 327.00K | 297.00K |
| ReconciledCostOfRevenue | 2.14M | 1.26M | 20.00K | 0.00 |
| EBITDA | -44.16M | -165.42M | -157.22M | -106.59M |
| EBIT | -44.47M | -165.74M | -157.54M | -106.89M |
| NetInterestIncome | -12.53M | -7.67M | -5.68M | 4.00K |
| InterestExpense | 15.13M | 13.31M | 8.21M | 40.00K |
| InterestIncome | 2.60M | 5.65M | 2.53M | 44.00K |
| NormalizedIncome | -57.16M | -174.89M | -165.76M | -106.93M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -59.60M | -179.05M | -165.76M | -106.93M |
| TotalExpenses | 67.07M | 169.00M | 160.02M | 106.94M |
| TotalOperatingIncomeAsReported | -67.25M | -171.78M | -159.65M | -106.94M |
| DilutedAverageShares | 2.54M | 1.82M | 1.75M | 1.65M |
| BasicAverageShares | 2.54M | 1.82M | 1.75M | 1.65M |
| DilutedEPS | -23.51 | -98.40 | -94.72 | -64.80 |
| BasicEPS | -23.51 | -98.40 | -94.72 | -64.80 |
| DilutedNIAvailtoComStockholders | -59.60M | -179.05M | -165.76M | -106.93M |
| NetIncomeCommonStockholders | -59.60M | -179.05M | -165.76M | -106.93M |
| NetIncome | -59.60M | -179.05M | -165.76M | -106.93M |
| NetIncomeIncludingNoncontrollingInterests | -59.60M | -179.05M | -165.76M | -106.93M |
| NetIncomeContinuousOperations | -59.60M | -179.05M | -165.76M | -106.93M |
| PretaxIncome | -59.60M | -179.05M | -165.76M | -106.93M |
| OtherIncomeExpense | 17.73M | -3.77M | -427.00K | |
| OtherNonOperatingIncomeExpenses | 20.17M | 394.00K | -427.00K | |
| SpecialIncomeCharges | -2.44M | -4.16M | 0.00 | |
| RestructuringAndMergernAcquisition | 2.44M | 4.16M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | -12.53M | -7.67M | -5.68M | 4.00K |
| InterestExpenseNonOperating | 15.13M | 13.31M | 8.21M | 40.00K |
| InterestIncomeNonOperating | 2.60M | 5.65M | 2.53M | 44.00K |
| OperatingIncome | -64.80M | -167.62M | -159.65M | -106.94M |
| OperatingExpense | 64.93M | 167.74M | 160.00M | 106.94M |
| ResearchAndDevelopment | 30.43M | 84.33M | 91.24M | 52.71M |
| SellingGeneralAndAdministration | 34.49M | 83.41M | 68.76M | 54.23M |
| SellingAndMarketingExpense | 1.39M | 12.48M | 13.01M | 3.00M |
| GeneralAndAdministrativeExpense | 33.10M | 70.93M | 55.76M | 54.23M |
| OtherGandA | 19.67M | 29.72M | 19.92M | 29.72M |
| InsuranceAndClaims | 1.67M | 1.74M | 2.37M | 2.14M |
| SalariesAndWages | 11.76M | 39.46M | 33.47M | 22.37M |
| GrossProfit | 123.00K | 120.00K | 355.00K | 0.00 |
| CostOfRevenue | 2.14M | 1.26M | 20.00K | 0.00 |
| TotalRevenue | 2.27M | 1.38M | 375.00K | 0.00 |
| OperatingRevenue | 2.27M | 1.38M | 375.00K | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.10M | 1.87M | 1.76M | 1.75M |
| ShareIssued | 3.10M | 1.87M | 1.76M | 1.75M |
| NetDebt | 72.65M | 35.38M | ||
| TotalDebt | 102.95M | 101.04M | 93.84M | 1.10M |
| TangibleBookValue | -93.10M | -56.51M | 76.78M | 221.67M |
| InvestedCapital | 9.41M | 44.09M | 169.83M | 221.67M |
| WorkingCapital | 15.16M | 44.88M | 169.97M | 220.15M |
| NetTangibleAssets | -93.10M | -56.51M | 76.78M | 221.67M |
| CapitalLeaseObligations | 439.00K | 440.00K | 786.00K | 1.10M |
| CommonStockEquity | -93.10M | -56.51M | 76.78M | 221.67M |
| TotalCapitalization | 9.41M | 44.09M | 169.83M | 221.67M |
| TotalEquityGrossMinorityInterest | -93.10M | -56.51M | 76.78M | 221.67M |
| StockholdersEquity | -93.10M | -56.51M | 76.78M | 221.67M |
| RetainedEarnings | -650.20M | -590.60M | -411.55M | -245.79M |
| AdditionalPaidInCapital | 557.05M | 534.06M | 488.29M | 467.43M |
| CapitalStock | 49.00K | 30.00K | 28.00K | 28.00K |
| CommonStock | 49.00K | 30.00K | 28.00K | 28.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 131.44M | 130.21M | 129.08M | 17.77M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 109.21M | 102.94M | 96.18M | 1.10M |
| DerivativeProductLiabilities | 6.63M | 1.91M | 2.34M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 102.57M | 101.04M | 93.84M | 1.10M |
| LongTermCapitalLeaseObligation | 65.00K | 440.00K | 786.00K | 1.10M |
| LongTermDebt | 102.51M | 100.60M | 93.05M | |
| CurrentLiabilities | 22.23M | 27.27M | 32.90M | 16.67M |
| OtherCurrentLiabilities | 346.00K | 404.00K | 293.00K | |
| CurrentDebtAndCapitalLeaseObligation | 374.00K | 346.00K | 319.00K | 293.00K |
| CurrentCapitalLeaseObligation | 374.00K | 346.00K | 319.00K | 293.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 35.00K | 163.00K | 6.37M | 3.97M |
| PayablesAndAccruedExpenses | 21.82M | 26.76M | 26.12M | 12.41M |
| CurrentAccruedExpenses | 5.64M | 12.88M | 15.39M | 7.22M |
| InterestPayable | 0.00 | 736.00K | 3.17M | 0.00 |
| Payables | 16.19M | 13.88M | 10.73M | 5.18M |
| DuetoRelatedPartiesCurrent | 107.00K | 107.00K | 422.00K | 204.00K |
| TotalTaxPayable | 91.00K | 116.00K | 82.00K | 302.00K |
| AccountsPayable | 15.99M | 13.65M | 10.23M | 4.68M |
| TotalAssets | 38.34M | 73.70M | 205.85M | 239.44M |
| TotalNonCurrentAssets | 944.00K | 1.56M | 2.98M | 2.63M |
| OtherNonCurrentAssets | 87.00K | 87.00K | 925.00K | 86.00K |
| NetPPE | 857.00K | 1.47M | 2.06M | 2.54M |
| AccumulatedDepreciation | -1.50M | -1.19M | -885.00K | -602.00K |
| GrossPPE | 2.36M | 2.67M | 2.94M | 3.14M |
| Leases | 1.20M | 1.20M | 1.18M | 1.13M |
| ConstructionInProgress | 0.00 | 24.00K | ||
| OtherProperties | 976.00K | 1.25M | ||
| MachineryFurnitureEquipment | 777.00K | 777.00K | 788.00K | 739.00K |
| BuildingsAndImprovements | 382.00K | 688.00K | 976.00K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 37.39M | 72.14M | 202.87M | 236.81M |
| OtherCurrentAssets | 1.44M | 2.08M | 3.84M | 956.00K |
| PrepaidAssets | 5.29M | 2.78M | 3.07M | 2.89M |
| Inventory | 679.00K | 1.99M | 1.99M | 0.00 |
| FinishedGoods | 173.00K | 405.00K | 595.00K | |
| WorkInProcess | 0.00 | 651.00K | 708.00K | |
| RawMaterials | 506.00K | 935.00K | 682.00K | |
| Receivables | 131.00K | 71.00K | 248.00K | 0.00 |
| AccountsReceivable | 131.00K | 71.00K | 248.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 29.85M | 65.22M | 193.72M | 232.97M |
| CashAndCashEquivalents | 29.85M | 65.22M | 193.72M | 232.97M |
| CashFinancial | 232.97M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -72.03M | -155.03M | -135.48M | -82.60M |
| RepurchaseOfCapitalStock | 0.00 | |||
| RepaymentOfDebt | -2.50M | 0.00 | ||
| IssuanceOfDebt | 0.00 | 98.60M | 0.00 | |
| IssuanceOfCapitalStock | 39.69M | 27.03M | 0.00 | 100.99M |
| CapitalExpenditure | -20.00K | -139.00K | -445.00K | |
| InterestPaidSupplementalData | 7.97M | 7.55M | 2.70M | 40.00K |
| EndCashPosition | 29.85M | 65.22M | 193.72M | 232.97M |
| BeginningCashPosition | 65.22M | 193.72M | 232.97M | 213.12M |
| ChangesInCash | -35.37M | -128.50M | -39.24M | 19.85M |
| FinancingCashFlow | 36.66M | 26.52M | 96.24M | 102.45M |
| CashFlowFromContinuingFinancingActivities | 36.66M | 26.52M | 96.24M | 102.45M |
| NetOtherFinancingCharges | -528.00K | -1.02M | -2.65M | |
| ProceedsFromStockOptionExercised | 0.00 | 508.00K | 283.00K | 1.45M |
| NetCommonStockIssuance | 39.69M | 27.03M | 0.00 | 100.99M |
| CommonStockPayments | 0.00 | |||
| CommonStockIssuance | 39.69M | 27.03M | 0.00 | 100.99M |
| NetIssuancePaymentsOfDebt | -2.50M | 0.00 | 98.60M | 0.00 |
| NetLongTermDebtIssuance | -2.50M | 0.00 | 98.60M | 0.00 |
| LongTermDebtPayments | -2.50M | 0.00 | ||
| LongTermDebtIssuance | 0.00 | 98.60M | 0.00 | |
| InvestingCashFlow | 0.00 | -20.00K | -139.00K | -445.00K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -20.00K | -139.00K | -445.00K |
| NetPPEPurchaseAndSale | 0.00 | -20.00K | -139.00K | -445.00K |
| PurchaseOfPPE | 0.00 | -20.00K | -139.00K | -445.00K |
| OperatingCashFlow | -72.03M | -155.01M | -135.34M | -82.15M |
| CashFlowFromContinuingOperatingActivities | -72.03M | -155.01M | -135.34M | -82.15M |
| ChangeInWorkingCapital | -6.03M | 2.02M | 10.40M | 4.98M |
| ChangeInOtherWorkingCapital | 264.00K | |||
| ChangeInOtherCurrentLiabilities | -346.00K | -319.00K | -293.00K | -237.00K |
| ChangeInOtherCurrentAssets | 271.00K | 264.00K | ||
| ChangeInPayablesAndAccruedExpense | -5.06M | -722.00K | 16.83M | 4.85M |
| ChangeInAccruedExpense | -736.00K | 2.50M | 3.80M | 0.00 |
| ChangeInInterestPayable | -736.00K | 2.50M | 3.80M | 0.00 |
| ChangeInPayable | -4.33M | -3.22M | 13.03M | 4.85M |
| ChangeInAccountPayable | -4.33M | -3.22M | 13.03M | 4.85M |
| ChangeInPrepaidAssets | -1.87M | 2.89M | -3.90M | 103.00K |
| ChangeInInventory | 1.31M | -6.00K | -1.99M | 0.00 |
| ChangeInReceivables | -60.00K | 177.00K | -248.00K | 0.00 |
| ChangesInAccountReceivables | -60.00K | 177.00K | -248.00K | 0.00 |
| OtherNonCashItems | 7.32M | 3.53M | 1.94M | |
| StockBasedCompensation | 6.16M | 18.61M | 17.34M | 19.45M |
| DepreciationAmortizationDepletion | 309.00K | 318.00K | 327.00K | 297.00K |
| DepreciationAndAmortization | 309.00K | 318.00K | 327.00K | 297.00K |
| Depreciation | 309.00K | 318.00K | 327.00K | 297.00K |
| OperatingGainsLosses | -20.18M | -436.00K | 411.00K | 46.00K |
| GainLossOnInvestmentSecurities | -20.18M | -438.00K | 389.00K | |
| GainLossOnSaleOfPPE | 0.00 | 2.00K | 22.00K | 46.00K |
| NetIncomeFromContinuingOperations | -59.60M | -179.05M | -165.76M | -106.93M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BTAI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|